Akgun, YelizBakirdogen, SerkanKocak, Meral Gulay KadiogluBektas, SibelDemir, CerenAkbal, ErdemElmas, Sait2025-01-272025-01-2720190353-95041332-8166https://doi.org/10.3325/cmj.2019.60.431https://hdl.handle.net/20.500.12428/24866Aim To investigate the efficacy of adalimumab treatment in an experimental rat sclerosing encapsulated peritonitis (SEP) model. Methods The study involved 40 Wistar albino rats divided into four groups: chlorhexidine (CH) group, control group, CH + adalimumab group, and CH + resting group. The control group received normal saline intraperitoneally (i.p.). Other groups received 0.1% CH gluconate, 15% ethanol, and normal saline mixture i.p. for three weeks in order to induce SEP. CH + adalimumab group received 5 mg/kg adalimumab i.p. at the beginning of week 4 and week 6, while CH + resting group was followed-up for three weeks without applying any procedure after the onset of SEP. Rats in groups CH and control group were sacrificed on day 21, and rats in group CH + adalimumab and CH + resting were sacrificed on day 42. All groups were evaluated for peritoneal thickness, inflammation, vascularization, and fibrosis. Results CH + adalimumab group showed a significant decrease in peritoneal thickness, fibrosis score, and vascular score compared with CH group and CH + resting group. Conclusion Adalimumab can prevent SEP development.eninfo:eu-repo/semantics/openAccessNecrosis-Factor-AlphaEndothelial Growth-FactorRenin-Angiotensin SystemMechanismsExpressionInhibitorsFibrosisMmp-3BetaArticle60543143810.3325/cmj.2019.60.431Q3WOS:0005063574000062-s2.0-8507455028231686457Q2